Free Trial

Nuvectis Pharma (NVCT) to Release Earnings on Tuesday

Nuvectis Pharma logo with Medical background
Remove Ads

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) is expected to be posting its Q4 2024 quarterly earnings results before the market opens on Tuesday, March 4th. Analysts expect Nuvectis Pharma to post earnings of ($0.28) per share for the quarter.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Trading Down 0.3 %

NVCT traded down $0.02 during mid-day trading on Friday, hitting $6.69. 28,728 shares of the stock were exchanged, compared to its average volume of 114,701. The firm's fifty day moving average is $6.26 and its two-hundred day moving average is $6.41. Nuvectis Pharma has a 1-year low of $4.44 and a 1-year high of $12.10. The company has a market cap of $129.26 million, a PE ratio of -5.77 and a beta of 0.22.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their target price on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday.

View Our Latest Stock Analysis on Nuvectis Pharma

Remove Ads

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of Nuvectis Pharma stock in a transaction dated Friday, February 7th. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the acquisition, the insider now owns 2,884,121 shares of the company's stock, valued at $14,420,605. This trade represents a 9.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased 261,500 shares of company stock valued at $1,300,825 in the last quarter. Corporate insiders own 35.78% of the company's stock.

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Featured Articles

Earnings History for Nuvectis Pharma (NASDAQ:NVCT)

Should You Invest $1,000 in Nuvectis Pharma Right Now?

Before you consider Nuvectis Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.

While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

NVIDIA is falling closer to the $100 mark—could it drop even further? Analysts predict up to 50% upside; is this a buying opportunity or a warning sign?

Related Videos

Is There Still Money in AI? How to Invest in the Next Big Wave
3 AI Stocks to Watch After NVIDIA’s Dip
5 Stocks to BUY NOW in March 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads